Alba Méndez-Gallego

Alba Méndez-Gallego

Auto-generated profile, based on publicly available information

Alba Méndez-Gallego

Hospital Universitario de Cabueñes, Gijón, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2022 in Advances in Hematology
Verified
Journal Article
Open access
PDF file
FCFrancisco Javier Cepeda-Piorno
Francisco Javier Cepeda-Piorno
EGEsther González-García
Esther González-García
AMAlba Méndez-Gallego
Alba Méndez-Gallego
JTJuan Torres-Varona
Juan Torres-Varona
VGVanesa García-Moreira
Vanesa García-Moreira
SGSegundo Gonzalez
Segundo Gonzalez
Objectives. The aim of this study was to compare the creatinine equations with cystatin C (CysC) equations to define renal impairment (RI) in newly diagnosed multiple myeloma (MM) patients and to analyse the equation that allows for identifying patients with more and worse prognostic factors. Methods. Renal function was evaluated prospectively in 61 patients with newly diagnosed untreated MM employing CKD-EPI and CAPA equations. The comparison was conducted using BlandAltman graphics and Cohens Kappa statistic. MannWhitney T and Chi-square tests were used, and univariate and multivariate analyses were carried out. Results. According to the IMWG criteria, 26 of patients showed RI (3 women/13 men) whilst the use of CysC equations allowed us to identify up to 39 of patients (7 women/17 men). The CAPA equation was less biased and dispersed and more sensitive than CKD-EPI-creatinine. Furthermore, univariate analysis unveiled an association between decreased CKD-EPI-CysC and poor prognosis based on R-ISS-3. Conclusions. The IMWG criteria may underestimate kidney disease, mostly in women, which could affect the dose received as well as its toxicity. Altogether, our data suggest that equations that include CysC are more accurate to detect hidden kidney disease, as well as patients with more and worse prognostic factors, in newly diagnosed MM.